Feng Yang is an accomplished Executive Director in Clinical Pharmacology and Pharmacometrics, currently leading efforts at Structure Therapeutics. They have over 15 years of experience in drug development, previously holding senior roles at Eli Lilly, Regeneron, and Alexion Pharmaceuticals, where they drove innovative modeling and simulation strategies. Feng earned a Ph.D. in Chemical Engineering and a Master's in Computer Science from the University of Rhode Island, enhancing their expertise in systems biology and pharmacometrics. Their collaborative leadership style and commitment to business needs have significantly contributed to high-performing teams and impactful drug development initiatives.
This person is not in any teams
This person is not in any offices